Investigating the Role of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction: The Link to Dapagliflozin
Clinical Scorecard: Investigating the Role of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction: The Link to Dapagliflozin
At a Glance
Category Detail
Condition Heart Failure with Preserved Ejection Fraction (HFpEF) Key Mechanisms Epicardial adipose tissue (EAT) influences myocardial remodeling and hemodynamics. Target Population Patients > 18 years old with BMI > 27 kg/m2 and left ventricular diastolic dysfunction. Care Setting Emergency room, out-patient clinic, or echo-lab.
Key Highlights
EAT is linked to worse outcomes in HFpEF. Dapagliflozin may reduce EAT volume and improve heart failure symptoms. Echocardiography and cardiac MRI are used to assess EAT. Guideline-Based Recommendations
Diagnosis
Echocardiography to confirm diastolic dysfunction and preserved ejection fraction. Elevated natriuretic peptides support HFpEF diagnosis. Management
Dapagliflozin 10 mg once daily in addition to standard medical therapy. Monitoring & Follow-up
Follow-up echocardiography and cardiac MRI after 6 months. Risks
Exclusion of patients with significant renal impairment, uncontrolled hypertension, or recent cardiovascular events. Patient & Prescribing Data
Patients with LV diastolic dysfunction and HFpEF.
Dapagliflozin shows potential for reducing epicardial fat despite minimal weight loss.
Clinical Best Practices
Utilize echocardiography for initial assessment of EAT. Consider cardiac MRI for comprehensive evaluation of EAT volume. Related Resources & Content
